- Innovations
- Newsletter
- …
- Innovations
- Newsletter
- Innovations
- Newsletter
- …
- Innovations
- Newsletter
Company Highlights
- Growth-stage, innovation driven, impact oriented Women’s Health Company
- Painless, radiation-free solutions for breast & cervical cancer detection
- US FDA cleared product has pre-screened 500,000 women in 10 countries
- Global commercialization in collaboration with Pfizer, Siemens & others
- High-margin recurring revenue model in multibillion-dollar global market
- Awarded by The World Bank, IFC. Recognized by WHO & ACOG TV
- Featured in the New York Times, Forbes, BBC, Vogue, & TED Talks
News!
Jan 18 > Siemens Medical Distribution Agreement Announced
Jan 5 > Global Women's HealthTech Award from The World Bank, IFC & CTA
Dec 24 > "Full Body Goosebump!" - Motley Fool Podcast discusses UELS
Nov 17 > UE LifeSciences wins the Innovation Challenge!
Nov 9 > $1,000,000 in investment commitments received in the first week.
Nov 2 > unanimous commitment of investment from the Circle of Money panel at the Unicorn Hunters Read Press Release
Too Many Women Are Dying
From Preventable Cancers
Problem Statement
Breast and cervical cancers are the most common and lethal cancers in the world for women. Globally, 90% of women have limited access to early detection— most get diagnosed at stage 3 and 4, with poor prognosis.
Early Detection can
save Millions of Lives
Solution
We are a women’s health company laser-focused on preventive oncology. We design, develop and commercialize hand-held, non-invasive, effective and easy to use medical devices and app-based platforms - built for mass adoption in B2B settings and soon for the consumer’s self-use, at home (B2C).
We’re commercializing and developing new breakthrough sensor technologies that can detect tumors and lesions instantly at the point of care, without requiring expert interpretation, virtually in any setting and without any pain or radiation.
Products Built for Scale
breakthrough products designed for massive scale across B2B & B2C markets.
iBreastExam (B2B)
Award-winning, patent-pending, radiation-free, ultra-portable wireless device, usable by lay health-workers to identify and document small, non-palpable lumps, quickly and easily, at the point-of-care.
FDA cleared. In commercialization.
cervAIcal (B2B)
AI enabled mobile colposcope
for cervical cancer screening. CervAIcal is a high-quality, wireless universal cervical examination assistant that goes where the patients are. Ongoing Pilots.Selfi (B2C)
World's first, at home
breast health monitoring
device / app / platform
built with iBreastExam technologyCommercial launch expected in 2022
Validations, Approvals
Partnerships, Awards & PressTraction
As we continue developing and commercializing our proprietary products, UE LifeSciences has secured major research milestones, commercial partnerships, multiple international awards, and press features.
450,000 women
examined and help diagnose 200+ cancer cases
Pfizer Collaboration
Global Agreement in April 21 to market & scale iBreastExam
>$3M in revenues
since 2018; from 750 devices and 1.5M scans
10 countries entered
with regulatory approvals & distribution channels
Validations & Publications by Global Experts & Clinical Advisors
Our Clinical Advisory Team consists of globally recognized experts and key opinion leaders in breast cancer control and treatment. 7,500 women have been enrolled in multiple investigator-led clinical validations with publications in leading international, peer-reviewed journals:
In conclusion, this study demonstrated excellent negative predictive value of iBE and agreement between iBE and CBE as triage tests for the detection of clinically relevant breast lesions.iBreastExam identified 15 women with a correlating BIRAD 4 score, of which 3 were confirmed as early-stage breast cancers (Stage IIA, IA and DCIS), none with palpable abnormality on clinical breast examination.97% of the participants reported the test as acceptable and recommendable to relatives and 98% expressed an interest to have iBreastExam made available at local Public Health Centers.This validation study demonstrated excellent sensitivity of iBE for the identification of clinically significant lesions in patients presenting for diagnostic imaging.Identified abnormalities in all 39 patients who presented with breast abnormalities and did not demonstrate any false negatives that would prevent the patients from additional evaluation, which makes it a good prescreening tool.iBreastExam demonstrated significantly (23%) higher sensitivity and moderately (9%) higher specificity to detect breast lesions as compared to CBE. Lower FP rates compared to CBE reduces the pool of women requiring further diagnostic follow-up. iBreastExam requires minimal training and provides objective breast examination with digital documentationAwards & Recognitions
2021 Thought Leader
ACOG TV, ACOG 2021 (American College of Obstetricians and Gynecologists Annual Meeting)
Innovative Health Technology
World Health Organization, Compendium of innovative health technologies for low-resource settings
$1.7M in Global Grant Awards
Innovation, Global Health & Oncology
Pennsylvania Department of Health, CURE Grant Award ($878,000)
Global Health Innovation Grant, Pfizer Foundation ($200,000)
Grants 4 Impact, Bayer Cares Foundation ($175,000)
StartHealth, Unitus Seed Fund ($80,000)
Digital Health Accelerator, University City Science Center ($50,000)
Helsinn – Lyfebulb Oncology Innovation Award ($25,000)
Aspirin Innovation Award, Bayer Cares Foundation ($20,000)
HITLabs World Cup Award NY
Accenture Healthcare Innovation Challenge Award
Inclusive Innovation Award, Anjani Mashelkar Foundation
Arab Health Innov8 Award, Dubai
Lexus Design Award, India
IBM Smart Camp for HealthTech India
Marcum Innovator of the Year Award
PACT Enterprise Awards LifeSciences Startup Company
Interested to invest? Let's go!
Over 100 years of team experience
Renowned Investors, KOL Advisors
People & Plans
Our team collectively brings together over 100 years of med-tech commercialization experience. We are backed by reputed investors and advisors.
We're at the Intersection of
Multiple Rapidly Growing Markets
Market
Women’s Health (or FemTech) set to be a $50B global market by Yr 2025.
Tele-Health is $22 billion US market in 2020, growing at a CAGR of 28%.
Increasing adoption of wearables, IoT and other med-devices at home.
UE LifeSciences Inc. Copyright © 2021 | Terms & Conditions | Privacy Policy